Details of the Drug
General Information of Drug (ID: DM32O0L)
Drug Name |
Edatrexate
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
EDATREXATE; 80576-83-6; TCMDC-137768; GNF-Pf-63; CHEMBL296373; 10-Ethyl-10-deazaaminopterin; CGP-30694; Edatrexate [USAN:INN]; Edatrexatum [INN-Latin]; Edatrexato [INN-Spanish]; Edatrexatum; Edatrexato; CGP 30694; EDX; psylliumseed; N-(p-(1-((2,4-Diamino-6-pteridinyl)methyl)propyl)benzoyl)-L-glutamic acid; L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)propyl)benzoyl)-; AC1OCESK; Edatrexate (USAN/INN); SCHEMBL4676; 10-ethyl-10-deazaaminopterine; CHEBI:135757
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 467.5 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | -0.4 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 10 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 5 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 11 | |||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References